In the November issue of MedNous, Dr Paula Salmikangas, Dr Björn Carlsson and Dr Steffen Thirstrup address the risks and challenges of gene editing.

In recent years, gene editing technologies have moved from non-clinical tests into first in human clinical studies. Although it is still in the early days, there are currently a substantial number of ongoing early-stage clinical trials as well as encouraging single case reports demonstrating proof-of-concept.

In this article, Drs Paula Salmikangas, Björn Carlsson and Steffen Thirstrup examine the most common techniques to change the genome, the risk of tumour-formation and off-target editing

Authors

Dr Paula Salmikangas

Director of Biopharmaceuticals and ATMP

Dr Björn Carlsson

Director of the NDA Advisory Board

Dr Steffen Thirstrup

LET’S TALK

You don't have to go it alone!

Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs

This field is for validation purposes and should be left unchanged.